1807988-02-8
- Product Name：Bictegravir Sodium
- Molecular Formula：C21H17F3N3NaO5
- Purity：99%
- Molecular Weight：471.4
Product Details:
CasNo： 1807988-02-8
Molecular Formula： C21H17F3N3NaO5
Factory Supply High Purity Bictegravir Sodium,Export 1807988-02-8 Fast Shipping
- Molecular Formula:C21H17F3N3NaO5
- Molecular Weight:471.4
Bictegravir Sodium(Cas 1807988-02-8) Usage
|
Description |
Bictegravir (BIC) is a potent integrase strand transfer inhibitor (INSTI) developed by Gilead Science as a therapy for HIV-1-infected patients. Biktarvy contains three different medicines: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir sodium belongs to the class of integrase strand transfer inhibitors, which are antiretroviral medications used to treat HIV infections. It inhibits the integrase enzyme, preventing the integration of viral DNA into the host genome, a crucial step in the replication of the HIV virus. |
|
Uses |
Bictegravir sodium is a key component of Biktarvy, a combination medication used for the treatment of HIV-1 infection. Biktarvy combines bictegravir sodium with emtricitabine and tenofovir alafenamide. It is indicated for use in both adults and children who have not previously received antiretroviral treatment or who have been stable on other regimens. This drug has a boxed warning. This is the most serious Food and Drug Administration (FDA) warning. A boxed warning alerts doctors and patients about drug effects that may be dangerous. In people who have hepatitis B and HIV, stopping certain HIV drugs such as Biktarvy can make existing hepatitis B worse. |
| Factory | Hangzhou Huarong Pharm Co., Ltd., founded in 2009, is dedicated to providing innovative products and services for small molecule drug discovery and development. The company specializes in research, development, and manufacturing across a range of fields, including Building Blocks, Reference Compounds & Impurities, Natural Products, APIs & Intermediates, and Antibody-drug Conjugates (ADCs). With a focus on R&D, Huarong Pharm has invested heavily in state-of-the-art facilities and GMP-certified plants. It has successfully served over 3,000 partners globally and aims to become a world leader in supporting life science innovation. The company’s core values are responsibility, teamwork, professionalism, efficiency, and continuous growth. |
1807988-02-8 Relevant articles
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications
Hanh Thi Pham &Thibault Mesplède
Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 4
This review provides an overview of the pharmacological and clinical information obtained from MEDLINE/PubMed publications and the latest international conferences.
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1
Said A. Hassounah, Ahmad Alikhani, Maureen Oliveira, Simrat Bharaj, Ruxandra-Ilinca Ibanescu, Nathan Osman, Hong-Tao Xu, Bluma G. Brenner, Thibault Mesplède , Mark A. Wainberg
, Antimicrobial Agents and Chemotherapy Vol. 61, No. 12
Two new investigational INSTIs termed bictegravir (BIC) and cabotegravir (CAB) are currently being tested in advanced clinical trials as part of daily oral and/or long-acting parenteral antiretroviral regimens.
Relevant Products
-
FezolinetantCAS：1629229-37-3
-
UbrogepantCAS：1374248-77-7
-
Avatrombopag maleateCAS：677007-74-8
